Oxybutynin Tablet, Film Coated, Extended Release
FDA Label NDC 70771-1086

1 label section · Submitted to the FDA by Zydus Lifesciences Limited · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Zydus Lifesciences Limited for the product Oxybutynin (NDC 70771-1086). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package Label.Principal Display Panel

Oxybutynin chloride extended-release tablets USP, 5 mg

NDC 70771-1086-1

100 tablets

Rx   only

Oxybutynin Chloride Extended-release Tablets (07a99aec 7de6 4468 963b C50850741855 01)

Oxybutynin Chloride Extended-release Tablets (07a99aec 7de6 4468 963b C50850741855 01)

Oxybutynin chloride extended-release tablets USP, 10 mg

NDC 70771-1087-1

100 tablets

Rx   only

Oxybutynin Chloride Extended-release Tablets (07a99aec 7de6 4468 963b C50850741855 02)

Oxybutynin Chloride Extended-release Tablets (07a99aec 7de6 4468 963b C50850741855 02)

Oxybutynin chloride extended-release tablets USP, 15 mg

NDC 70771-1088-1

100 tablets

Rx   only

Oxybutynin Chloride Extended-release Tablets (07a99aec 7de6 4468 963b C50850741855 03)

Oxybutynin Chloride Extended-release Tablets (07a99aec 7de6 4468 963b C50850741855 03)

* Please review the disclaimer below.